Teva Pharmaceutical Industries Limited

University of Kansas

Active Biotech Ab

Muhammad Safadi

Anton Frenkel

Daniella Licht

Ioana Lovinger

Valentino J Stella

Aharon Eyal

Jan J Zygmunt

Ingrid Gunda Georg

Karl Erik Jansson

Tomas Fristedt

Danit Licht

Rachel Cohen

Marina Zholkovsky

Ramy Lidor-Hadas

Eliezer Bahar

Rakefet Cohen

Sasson Habbah

Michal Keisar

Tamas Koltai

Avital Laxer

Konstantin Ulanenko

Ales Vrána

Vladimir Ioffe

Ulf Tomas Fristedt

Fanny Caciularu

Roman Stonis

Tomas Andrysek

Marie Elblova

The patent provides a process of preparing a pharmaceutical preparation of glatiramer acetate and mannitol in a suitable container comprising the steps of: This patent further provides an aqueous pharmaceutical solution comprising 40 mg/ml glatiramer acetate and 40 mg/ml mannitol, wherein the aqueous pharmaceutical solution This patent also provides a prefilled syringe, an automated injector and a method of treatment of a human patient.

Process for manufacturing glatiramer acetate product

The subject invention provides R(+)-N-formyl-propargyl-aminoindan and a composition containing N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of R(+)-N-formyl-propargyl-aminoindan.

R(+)-N-formyl-propargyl-aminoindan

The subject invention provides R(+)-N-methyl-propargyl-aminoindan or a pharmaceutically acceptable salt thereof and a composition containing R(+)-N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of R(+)-N-methyl-propargyl-aminoindan or a salt thereof.

R(+)-N-methyl-propargyl-aminoindan

The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid, 1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3'-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide.

Stable laquinimod preparations

The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.

N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof

Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties.

Delayed release rasagiline citrate formulation

The subject invention provides rasagiline citrate, its compositions and processes for the manufacture thereof.

Citrate salt of Rasagiline

The present invention is directed to novel water-soluble prodrugs of aliphatic or aromatic hindered hydroxyl group containing pharmaceuticals.

Water soluble prodrugs of hindered alcohols

Growing community of inventors

Nazareth, Israel

Muhammad Safadi